72
Participants
Start Date
November 15, 2019
Primary Completion Date
September 30, 2027
Study Completion Date
December 31, 2027
Granisetron
An antiemetic regimen containing granisetron 2 mg oral or IV.
Ondansetron
An antiemetic regimen containing ondansetron 8 mg oral or IV.
Palonosetron
An antiemetic regimen containing palonosetron 0.25 mg IV.
Memorial Sloan Kettering Cancer Center, New York
UCHealth-Metro Denver, Denver
Memorial Sloan Kettering Cancer Center
OTHER
Rutgers University
OTHER
National Institute of General Medical Sciences (NIGMS)
NIH
University of Colorado, Denver
OTHER